Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>QIAGEN N.V. reported preliminary results for the first quarter of 2026, revealing a mixed performance marked by solid profitability but sales slightly below prior expectations.</li>
<li>The company delivered adjusted diluted earnings per share (EPS) of $0.54 at constant exchange rates (CER), meeting its outlook despite a challenging macroeconomic environment and uneven sales across business segments.</li>
<li>Total net sales were $492 million, representing a 2% increase on a reported basis but a 1% decline at CER, falling short of the targeted minimum 1% CER growth.</li>
</ul>


QIAGEN N.V. reported preliminary results for the first quarter of 2026, revealing a mixed performance marked by solid profitability but sales slightly below prior expectations.
The company delivered adjusted diluted earnings per share (EPS) of $0.54 at constant exchange rates (CER), meeting its outlook despite a challenging macroeconomic environment and uneven sales across business segments.
Total net sales were $492 million, representing a 2% increase on a reported basis but a 1% decline at CER, falling short of the targeted minimum 1% CER growth.


QIAGEN’s Outlook Reset: Can Digital PCR And Sample Tech Offset QuantiFERON Weakness?

Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>QIAGEN is a global leader in Sample to Insight solutions, providing a broad portfolio of products for molecular diagnostics and life sciences research. The company's strategy is focused on five key growth pillars: sample technologies, QuantiFERON for latent TB testing, QIAstat-Dx for syndromic testing, QIAcuity digital PCR, and QIAGEN Digital Insights bioinformatics.</li>
 <li>The company is targeting solid, profitable growth with a goal of at least $2 billion in combined annual sales from its growth pillars by 2028. This is expected to be driven by new product launches, expansion into new markets, and a focus on recurring revenues from consumables.</li>
 <li>While navigating a post-pandemic landscape and facing a decline in COVID-19-related revenue, QIAGEN's core business remains strong. However, the company faces intense competition from larger players in the diagnostics and life sciences industry and needs to execute effectively on its growth strategy to drive shareholder value.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  QIAGEN is a global leader in Sample to Insight solutions, providing a broad portfolio of products for molecular diagnostics and life sciences research. The company's strategy is focused on five key growth pillars: sample technologies, QuantiFERON for latent TB testing, QIAstat-Dx for syndromic testing, QIAcuity digital PCR, and QIAGEN Digital Insights bioinformatics.
  The company is targeting solid, profitable growth with a goal of at least $2 billion in combined annual sales from its growth pillars by 2028. This is expected to be driven by new product launches, expansion into new markets, and a focus on recurring revenues from consumables.
  While navigating a post-pandemic landscape and facing a decline in COVID-19-related revenue, QIAGEN's core business remains strong. However, the company faces intense competition from larger players in the diagnostics and life sciences industry and needs to execute effectively on its growth strategy to drive shareholder value.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul>
<li>QIAGEN's third-quarter 2025 earnings call revealed both strengths and challenges that define the company's current performance and future outlook.</li>
<li>The company's focus on high-growth areas of molecular research and testing has led to a steady performance amidst a challenging macroeconomic environment, yet various strategic initiatives and external pressures influence its trajectory.</li>
<li>On the positive side, QIAGEN continues to demonstrate robust operational execution.</li>
</ul>


QIAGEN's third-quarter 2025 earnings call revealed both strengths and challenges that define the company's current performance and future outlook.
The company's focus on high-growth areas of molecular research and testing has led to a steady performance amidst a challenging macroeconomic environment, yet various strategic initiatives and external pressures influence its trajectory.
On the positive side, QIAGEN continues to demonstrate robust operational execution.


QIAGEN: Benefitting From Structural Demand Tailwinds in Molecular Diagnostics

<ul>
<li>QIAGEN's recent earnings call highlighted several points of interest for investors.</li>
<li>The company reported betterthan-expected results for Q1 2025, with net sales of $483 million, marking a 7% rise at constant exchange rates (CER) year-over-year.</li>
<li>Adjusted diluted earnings per share reached $0.50 at CER, surpassing initial forecasts.</li>
</ul>


QIAGEN's recent earnings call highlighted several points of interest for investors.
The company reported betterthan-expected results for Q1 2025, with net sales of $483 million, marking a 7% rise at constant exchange rates (CER) year-over-year.
Adjusted diluted earnings per share reached $0.50 at CER, surpassing initial forecasts.


QIAGEN:  How Digital Solutions Are Transforming Diagnostic Leadership!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Corrections across global ex-US markets continue to limit attractive investment opportunities from both a price and relative strength perspective.  We provide a recap and outlook for global equity markets and highlight individual opportunities across various markets within the Health Care, Communications and Transportation sectors.

Corrections across global ex-US markets continue to limit attractive investment opportunities from both a price and relative strength perspective.  We provide a recap and outlook for global equity markets and highlight individual opportunities across various markets within the Health Care, Communications and Transportation sectors.

Global Strategy: Carnage Continuation Amid Turkey Turmoil and US Dollar Breakout

United States

QIAGEN N.V. is a global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. The Company provides its workflows to customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

QIAGEN NV (QIA GY)

QIAGEN’s Outlook Reset: Can Digital PCR And Sample Tech Offset QuantiFERON Weakness?

QIAGEN N.V. reported preliminary results for the first quarter of 2026, revealing a mixed performance marked by solid profitability but sales...

Baptista Research

Primer: QIAGEN NV (QIA GY) - May 2026

QIAGEN is a global leader in Sample to Insight solutions, providing a broad portfolio of products for molecular diagnostics and life sciences...

αSK

QIAGEN: Benefitting From Structural Demand Tailwinds in Molecular Diagnostics

QIAGEN's third-quarter 2025 earnings call revealed both strengths and challenges that define the company's current performance and future outlook.

Baptista Research

QIAGEN: How Digital Solutions Are Transforming Diagnostic Leadership!

The company reported betterthan-expected results for Q1 2025, with net sales of $483 million, marking a 7% rise at constant exchange rates (CER)...

Baptista Research

Global Strategy: Carnage Continuation Amid Turkey Turmoil and US Dollar Breakout

Corrections across global ex-US markets continue to limit attractive investment opportunities from both a price and relative strength perspective. ...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)